von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura

被引:77
作者
Allford, SL
Harrison, P
Lawrie, AS
Liesner, R
Mackie, IJ
Machin, SJ
机构
[1] UCL, Dept Haematol, London WC1E 6HX, England
[2] Great Ormond St Hosp Sick Children, London WC1N 3JH, England
关键词
von Willebrand factor-cleaving protease; thrombotic thrombocytopenic purpura; congenital; therapy; factor VIII concentrates;
D O I
10.1046/j.1365-2141.2000.02503.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombotic thrombocytopenic purpura (TTP) is characterized by microangiopathic haemolytic anaemia (MAHA), thrombocytopenia, fluctuating neurological impairment, renal dysfunction and fever. Both acquired and congenital forms are recognized. Recurrent episodes, which may be predictable (occurring every 21-28 d), are seen in congenital disease and may be treated by infusion with Fresh-frozen plasma (FFP). Congenital TTP has recently been associated with deficiency of a novel von Willebrand factor (VWF)-cleaving protease. To investigate whether residual protease activity dictates clinical manifestations, we determined protease activity in three patients with congenital TTP of varying severity. Intrinsic VWF-cleaving protease activity of a range of plasma-derived products was also assessed as one patient had been successfully maintained for many years, initially using an Intermediate-purity factor VIII concentrate (Kryobulin) and then cryoprecipitate. All three patients had a severe absolute deficiency of VWF-cleaving protease activity (< 3%) up to 5 months after clinical symptoms. Three relatives were also found to have a mild reduction in protease activity (25-50%). Nevertheless, the intrinsic VWF-cleaving protease activity of plasma-derived products correlated with their clinical efficacy: significant (100%) protease activity was found in FFP, cryosupernatant, solvent-detergent-treated plasma, cryoprecipitate and Kryobulin. Two clinically ineffective factor VIII products (Fahndi and Haemate P) possessed only low protease activity (6.25% and 12.5% respectively). Although this suggests that VWF-cleaving protease activity is central to the pathogenesis of congenital TTP, either small differences in protease activity below 3% or hitherto unknown factors have a profound influence on clinical phenotype. The possible use of factor VIII concentrates in the treatment of this condition also warrants further investigation.
引用
收藏
页码:1215 / 1222
页数:8
相关论文
共 27 条
  • [1] Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment
    Aird, WC
    Edelberg, JM
    WeilerGuettler, H
    Simmons, WW
    Smith, TW
    Rosenberg, RD
    [J]. JOURNAL OF CELL BIOLOGY, 1997, 138 (05) : 1117 - 1124
  • [2] Barbot J., 2000, Haemostasis, V30, P193
  • [3] CHRONIC RELAPSING THROMBOTIC THROMBOCYTOPENIC PURPURA IN INFANTS WITH LARGE VONWILLEBRAND-FACTOR MULTIMERS DURING REMISSION
    CHINTAGUMPALA, MM
    HURWITZ, RL
    MOAKE, JL
    MAHONEY, DH
    STEUBER, CP
    [J]. JOURNAL OF PEDIATRICS, 1992, 120 (01) : 49 - 53
  • [4] IDENTIFICATION OF A CLEAVAGE SITE DIRECTING THE IMMUNOCHEMICAL DETECTION OF MOLECULAR ABNORMALITIES IN TYPE-IIA VONWILLEBRAND-FACTOR
    DENT, JA
    BERKOWITZ, SD
    WARE, J
    KASPER, CK
    RUGGERI, ZM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (16) : 6306 - 6310
  • [5] DRAKE TA, 1993, AM J PATHOL, V142, P1458
  • [6] TRIPLET STRUCTURE OF VON-WILLEBRAND-FACTOR REFLECTS PROTEOLYTIC DEGRADATION OF HIGH-MOLECULAR-WEIGHT MULTIMERS
    FURLAN, M
    ROBLES, R
    AFFOLTER, D
    MEYER, D
    BAILLOD, P
    LAMMLE, B
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (16) : 7503 - 7507
  • [7] Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura
    Furlan, M
    Robles, R
    Solenthaler, M
    Wassmer, M
    Sandoz, P
    Lammle, B
    [J]. BLOOD, 1997, 89 (09) : 3097 - 3103
  • [8] Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
    Furlan, M
    Robles, R
    Galbusera, M
    Remuzzi, G
    Kyrle, PA
    Brenner, B
    Krause, M
    Scharrer, I
    Aumann, V
    Mittler, U
    Solenthaler, M
    Lämmle, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) : 1578 - 1584
  • [9] Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis
    Furlan, M
    Robles, R
    Lammle, B
    [J]. BLOOD, 1996, 87 (10) : 4223 - 4234
  • [10] GORDON LI, 1987, SEMIN HEMATOL, V24, P194